TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.
作者信息
Schimmer Roman R, Kovtonyuk Larisa V, Klemm Nancy, Fullin Jonas, Stolz Sebastian M, Mueller Jan, Caiado Francisco, Kurppa Kari J, Ebert Benjamin L, Manz Markus G, Boettcher Steffen
机构信息
Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.
Comprehensive Cancer Center Zurich, Zurich, Switzerland.
出版信息
Blood Adv. 2022 Jun 14;6(11):3201-3206. doi: 10.1182/bloodadvances.2021005859.
Abstract
摘要
Zotero 插件